Predictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial

This publication has 19 references indexed in Scilit:

• Effect of Anemia on Hemorrhagic Complications and Mortality Following Percutaneous Coronary Intervention
  The American Journal of Cardiology, 2007
• Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk
  Heart, 2006
• Bivalirudin
  Drugs, 2005
• Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications
  Circulation, 2004
• Bivalirudin
  Drugs, 2002
• Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparisons With a Low-Molecular-Weight Heparin and With a Direct Thrombin Inhibitor
  Circulation, 1998
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.
  Circulation, 1994
• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
  Journal of Clinical Investigation, 1990
• Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
  Journal of the American College of Cardiology, 1988